Egetis Therapeutics (EGTX) Q2 2025 earnings summary

Executive summary

• FDA granted Breakthrough Therapy Designation for tiratricol in July 2025, expediting US regulatory review based on robust survival data from an international cohort study.

• Emcitate (tiratricol) launched commercially in Germany on May 1, 2025, marking the first EU commercialization for MCT8 deficiency treatment and transition to a commercial-stage company.

• Pre-NDA meeting request submitted to FDA in August 2025 to discuss US regulatory pathway; NDA submission planned for 2025.

• Exclusive distribution agreements signed for Türkiye, with advanced plans for the Middle East, North Africa, and Japan.

• Expanded Access Program for tiratricol active in the US, with 14 hospitals participating and over 100 patients identified.

Financial highlights

• H1 2025 revenues were SEK 27.1 million, up from SEK 25.9 million year-over-year; Q2 revenues were SEK 14.5 million, up from SEK 13.9 million.

• Adjusted gross margin for H1 2025 was 80%, up from 78% in H1 2024, reflecting improvement after excluding non-recurring milestone payments and R&D depreciation.

• Operating loss for H1 2025 was -SEK 143.1 million, nearly flat year-over-year; after-tax loss improved to -SEK 140.5 million from -SEK 146.9 million.

• Cash position at end of June 2025 was SEK 202.6 million, up from SEK 192.6 million last year.

• Cash flow for H1 2025 was -SEK 143.4 million, compared to -SEK 113 million last year; equity ratio at 54% (down from 62%).

Outlook and guidance

• Preparing for US NDA submission, with a pre-NDA (type B) meeting requested for October and submission planned for 2025.

• No revenue guidance provided for 2025 due to ongoing pricing and reimbursement processes in key EU markets.

• Key milestones for 2025-2026 include US NDA submission, potential US approval and launch, expansion into MENA and Japan, and completion of the ReTRIACt trial.

• US Rare Pediatric Disease Priority Review Voucher anticipated upon approval.

• Ongoing discussions with BlackRock regarding extension of EUR 15 million loan facility.